IMV Inc. Appoints Julia P. Gregory to Board of Directors
June 07 2018 - 7:05AM
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq:IMV) (TSX:IMV), a
clinical stage immunotherapy company, announced today the addition
of Julia P. Gregory to the company’s Board of Directors.
Andy Sheldon, IMV Chairman of the Board,
commented, “Julia’s experience is an ideal addition to our Board
given the Company’s anticipated near-term milestones and long-term
strategic vision. She brings a uniquely rich background in the
strategic financing, planning, partnering, and growth of public
biotech companies. We are eager to leverage her counsel as our
immuno-oncology programs enter another significant stage of
growth.”
“It is with great enthusiasm that I join Andy
and the other members of the Board to work with IMV’s world-class
research and drug development teams on a new class of
transformative immunotherapies,” stated Ms. Gregory. “I look
forward to the opportunity to work with IMV as the company advances
its clinical programs and candidates to address some of the most
significant unmet needs in the cancer treatment landscape.”
Ms. Gregory is a seasoned biotechnology
executive with Chief Executive Officer, Chief Financial Officer,
Board and investment banking experience. She recently served as
Chief Executive Officer and Board Member of ContraFect Corporation,
a public biotechnology company developing innovative
anti-infectives. Prior to this engagement, she served as the Chief
Executive Officer of the immuno-oncology company Five Prime.
Ms. Gregory has a proven track record of
successfully growing, capitalizing, and positioning private and
public biotechnology companies. As a biotechnology executive, she
has raised more than $1.5 billion across all types of business
cycles and structured creative strategic alliances and transactions
with pharmaceutical companies including GlaxoSmithKline,
Bristol-Myers Squibb Company, Takeda Pharmaceutical Company, Ltd.,
Genentech, Inc. (now Roche), and Human Genome Sciences (now GSK).
She is currently on the Board of Directors of Iconic Therapeutics,
the Sosei Group and Biohaven Therapeutics.
About IMV
IMV Inc., formerly Immunovaccine, is a
clinical stage biopharmaceutical company dedicated to making
immunotherapy more effective, more broadly applicable, and more
widely available to people facing cancer and other serious
diseases. IMV is pioneering a new class of immunotherapies based on
the Company’s proprietary drug delivery platform. This patented
technology leverages a novel mechanism of action that enables the
reprogramming of immune cells in vivo, which are aimed at
generating powerful new synthetic therapeutic capabilities. IMV’s
lead candidate, DPX-Survivac, is a T cell activating immunotherapy
that combines the utility of the platform with a target: survivin.
IMV is currently conducting three Phase 2 studies with Incyte and
Merck assessing DPX-Survivac as a combination therapy in ovarian
cancer and diffuse large B-cell lymphoma. Connect
at www.imv-inc.com.
IMV Forward-Looking
Statements
This press release contains forward-looking
information under applicable Canadian and U.S. securities law. All
information that addresses activities or developments that we
expect to occur in the future is forward-looking information.
Although the Corporation believes the forward-looking statements in
this press release are reasonable, it can give no assurance that
the expectations and assumptions in such statements will prove to
be correct. The Corporation cautions investors that any
forward-looking statements by the Corporation are not guarantees of
future results or performance, and that actual results may differ
materially from those in forward-looking statements as a result of
various factors, including, but not limited to, the matters
discussed under “Risk Factors and Uncertainties” in IMV’s Annual
Information Form filed in Canada on March 20, 2018 on
www.sedar.com and included in the company’s Form 40-F filing in the
United States with the United States Securities and Exchange
Commission filed on May 1, 2018 on www.sec.gov. IMV Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for IMV:
MEDIA Mike Beyer, Sam Brown Inc. T: (312)
961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONS Pierre Labbé, Chief
Financial Officer T: (902) 492-1819 E: info@imv-inc.com
Patti Bank, Managing Director, Westwicke
Partners O: (415) 513-1284 T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024